Squamous Cell Neoplasm

124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival… (full text at CIViC)

PMID 27414035 · Li et al., 2016 · Open in CIViC

Case report of a 73 year old patient with advanced squamous cell carcinoma of the lung that tested negative for EGFR, KRAS and PIK3CA mutations and ALK and ROS1 rearrangements. c-MET amplification was… (full text at CIViC)

PMID 24192513 · Schwab et al., 2014 · Open in CIViC

In a metastatic lung squamous cell carcinoma patient harboring a MET D1010N mutation, MET D1010N mutation was associated with response to crizotinib monotherapy. The patient maintained initial respons… (full text at CIViC)

PMID 27022036 · Heist et al., 2016 · Open in CIViC

Collectively data from expression analysis of 102 esophageal squamous cell carcinoma (ESCC) sample tissues established MYC and HSP90 as potential targets with overexpression of MYC observed in over ha… (full text at CIViC)

PMID 32308431 · Guan et al., 2020 · Open in CIViC

In a cohort of 178 patients with lung squamous cell carcinoma from The Cancer Genome Atlas, high neoantigen burden was significantly associated with improved disease-free survival compared with low ne… (full text at CIViC)

PMID 30824826 · Chae et al., 2019 · Open in CIViC

In a mutational analysis of 1,145 primary cancers, NFE2L2 (NRF2) mutations occurred predominantly in squamous cell carcinomas (SCCs) of the esophagus (11.4%), skin (6.3%), lung (15.8%), and larynx (13… (full text at CIViC)

PMID 19967722 · Kim et al., 2010 · Open in CIViC

In a phase 2 trial, patients with squamous cell lung carcinoma harboring NFE2L2 mutation were treated with oral TORC1/2 inhibitor TAK228. ORR 25% (1 PR, 3 SD, 0 PD).

Open in CIViC

In an NCI-CTEP phase 2 trial, patients with squamous cell lung carcinoma with NFE2L2 mutations were treated with TORC1/2 inhibitor TAK-228. The response rate was 29% (2/7）and disease control rate was …

In a phase II, nonrandomized, single-arm trial (NCT03740100), 8 patients with recurrent/metastatic HNSCC harboring NOTCH1 mutations predicted to cause loss of function received bimiralisib after prior… (full text at CIViC)

PMID 36124629 · Johnson et al., 2022 · Open in CIViC

In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome seq… (full text at CIViC)

PMID 24277854 · Liu et al., 2013 · Open in CIViC

From 31 patients with advanced cutaneous squamous cell carcinomas evaluated for mutations in RAS, BRAF, and EGFR genes, only 2 RAS mutated samples (6.5%) were identified. Patients with NRAS p.G12D (c.… (full text at CIViC)

PMID 28259104 · Picard et al., 2017 · Open in CIViC

In non-HER2 amplified cell lines, sensitivity to HER2 kinase inhibitor lapatinib was found mainly in cell-lines with elevated NRG1 expression and HER3 activation. This aberration was mainly identified… (full text at CIViC)

PMID 21840482 · Wilson et al., 2011 · Open in CIViC

Cell line NCI-H1703 is PDGFRA amplified and KIT wild-type. NCI-H1703 was treated with a PDGFRA inhibitor, imatinib or sunitinib. The IC50 of imatinib or sunitinib was lower in PDGFRA amplified NCI-H… (full text at CIViC)

PMID 19755855 · Ramos et al., 2009 · Open in CIViC

In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation,… (full text at CIViC)

PMID 30683736 · Hedberg et al., 2019 · Open in CIViC

The HNSCC cell line LB771 with PIK3CA amplification was shown to have low antiproliferative IC50 for the p110beta-sparing PI3K inhibitor taselisib. Under increasing taselisib concentrations, reduction… (full text at CIViC)

PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC

Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirm… (full text at CIViC)

PMID 26787751 · Dolly et al., 2016 · Open in CIViC

The Cal-33 HNSCC cell line with H1047R mutation was found to have a low antiproliferative IC50 value for the alpha, gamma and delta isoform-specific PI3K inhibitor taselisib. Increasing taselisib conc… (full text at CIViC)

PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC

In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation,… (full text at CIViC)

PMID 30683736 · Hedberg et al., 2019 · Open in CIViC

A panel of 26 HNSCC cell lines was tested for efficacy of the p110 alpha, delta and gamma isoform inhibitor taselisib (GDC-0032). Cell lines with PIK3CA mutation or amplification were the most sensiti… (full text at CIViC)

PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC

In this pre-clinical study, the role of the non-canonical PIK3CA mutation PIK3CA Q75E was evaluated. The expression of pKAT/total AKT was compared across canonical PIK3CA E545K mutation, non-canonical… (full text at CIViC)

PMID 34779417 · Jin et al., 2021 · Open in CIViC

A 55-year-old man with HNSCC harbouring PIK3CA Q75E (non-canonical) mutation was previously treated and responded to concurrent chemoradiation therapy (CRT) with cisplatin, however, experienced local … (full text at CIViC)

PMID 34779417 · Jin et al., 2021 · Open in CIViC

In a panel of 26 HNSCC cell lines tested for sensitivity to taselisib (an alpha, delta and gamma isoform-specific PI3K inhibitor) the UD-SCC-2 cell line with homozygous PTEN deletion had considerably … (full text at CIViC)

PMID 26589432 · Zumsteg et al., 2016 · Open in CIViC

PTPRT promoter hypermethylation was associated with increased sensitivity to STAT3 inhibition in this preclinical study in HNSCC. The authors found that PTPRT promoter methylation and sensitivity to S… (full text at CIViC)

PMID 25982282 · Peyser et al., 2016 · Open in CIViC

In this study, SMAD4 underexpression was associated with an epithelial-to-mesenchymal transition and resistance to EGFR-directed treatment with Cetuximab.

PMID 26046389 · Cheng et al., 2015 · Open in CIViC

Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC)

PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC

This retrospective analysis of the Phase 3 EAGLE trial (NCT02369874) evaluated tissue tumor mutational burden (tTMB) and blood TMB (bTMB) as predictive biomarkers in platinum-refractory recurrent or m… (full text at CIViC)

PMID 36806911 · Wildsmith et al., 2023 · Open in CIViC

This observational cohort study assessed the association between total mutational burden (TMB) and the efficacy of anti-PD-1/L1 therapy in head and neck squamous cell carcinoma. Using large comprehens… (full text at CIViC)

PMID 29467336 · Hanna et al., 2018 · Open in CIViC

This is part of the randomised double-blind phase 3 trial, CameL-sq, a study that assessed the therapeutic effectiveness of the PD-1 blockade, camrelizumab plus chemotherapy as first-line treatment in… (full text at CIViC)

PMID 34980131 · Jiang et al., 2022 · Open in CIViC

In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those witho… (full text at CIViC)

PMID 22090360 · Skinner et al., 2012 · Open in CIViC

Oral squamous cell carcinoma patients with TP53 mutations in the DNA binding domain (L2, L3 and the LSH motif) have significantly reduced cumulative survival when compared to patients with TP53 mutati… (full text at CIViC)

PMID 12509970 · Yamazaki et al., 2003 · Open in CIViC

In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.

PMID 19941080 · Yamasaki et al., 2010 · Open in CIViC

Tumors from 114 patients with head and neck squamous cell carcinoma were analyzed for TP53 mutations, 21 of which were treated with surgery. Unlike those treated with radiotherapy, those treated with … (full text at CIViC)

PMID 11325447 · Alsner et al., 2001 · Open in CIViC

In a retrospective study of 23 patients with BRAF V600 mutation (a known vemurafenib sensitizing mutation) that developed cutaneous squamous-cell carcinoma upon treatment with vemurafenib monotherapy,… (full text at CIViC)

PMID 22256804 · Su et al., 2012 · Open in CIViC

In patients with head and neck squamous cell carcinoma, in a multivariate analysis those with truncating mutations in TP53 had worse progression-free and overall survival than wild-type patients.

PMID 21467160 · Lindenbergh-van der Plas et al., 2011 · Open in CIViC

In patients with head and neck squamous cell carcinoma, when comparing patients with any mutation in TP53 to wild-type, there was not a significant difference in overall survival in a multivariate ana… (full text at CIViC)

PMID 21467160 · Lindenbergh-van der Plas et al., 2011 · Open in CIViC

Analysis of 77 esophageal squamous cell carcinoma tumor and normal samples for germline mutations revealed a rare TP53 V197E variant in a single patient. The V197E mutation is in the DNA-binding domai… (full text at CIViC)

PMID 30833958 · Deng et al., 2019 · Open in CIViC

Within a preclinical study the inhibitory effects of AZD1775 in esophageal squamous cell carcinoma (ESCC) was demonstrated in both in vitro and in-vivo samples that predominantly displayed high expres… (full text at CIViC)

PMID 31427973 · Bi et al., 2019 · Open in CIViC